Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing.
Kangarloo SB, Naveed F, Ng ES, Chaudhry MA, Wu J, Bahlis NJ, Brown CB, Daly A, Duggan P, Geddes M, Quinlan D, Savoie ML, Shafey M, Stewart DA, Storek J, Yang M, Zacarias N, Yue P, Magliocco AM, Russell JA. Kangarloo SB, et al. Among authors: shafey m. Biol Blood Marrow Transplant. 2012 Feb;18(2):295-301. doi: 10.1016/j.bbmt.2011.07.015. Epub 2011 Jul 27. Biol Blood Marrow Transplant. 2012. PMID: 21801704 Free article. Clinical Trial.
Fludarabine, busulfan, antithymocyte globulin, and total body irradiation for pretransplantation conditioning in acute lymphoblastic leukemia: excellent outcomes in all but older patients with comorbidities.
Daly A, Savoie ML, Geddes M, Chaudhry A, Stewart D, Duggan P, Bahlis N, Storek J, Brown C, Shafey M, Turner AR, Russell J. Daly A, et al. Among authors: shafey m. Biol Blood Marrow Transplant. 2012 Dec;18(12):1921-6. doi: 10.1016/j.bbmt.2012.07.017. Epub 2012 Jul 27. Biol Blood Marrow Transplant. 2012. PMID: 22842330 Free article.
Establishing a target exposure for once-daily intravenous busulfan given with fludarabine and thymoglobulin before allogeneic transplantation.
Russell JA, Kangarloo SB, Williamson T, Chaudhry MA, Savoie ML, Turner AR, Larratt L, Storek J, Bahlis NJ, Shafey M, Brown CB, Yang M, Geddes M, Zacarias N, Yue P, Duggan P, Stewart DA, Daly A. Russell JA, et al. Among authors: shafey m. Biol Blood Marrow Transplant. 2013 Sep;19(9):1381-6. doi: 10.1016/j.bbmt.2013.07.002. Epub 2013 Jul 17. Biol Blood Marrow Transplant. 2013. PMID: 23871781 Free article.
Outcomes of Consecutively Diagnosed Primary Central Nervous System Lymphoma Patients Using the Alberta Lymphoma Clinical Practice Guideline Incorporating Thiotepa-Busulfan Conditioning for Transplantation-Eligible Patients.
Sanders S, Chua N, Larouche JF, Owen C, Shafey M, Stewart DA. Sanders S, et al. Among authors: shafey m. Biol Blood Marrow Transplant. 2019 Aug;25(8):1505-1510. doi: 10.1016/j.bbmt.2019.04.004. Epub 2019 Apr 6. Biol Blood Marrow Transplant. 2019. PMID: 30965138 Free article. Clinical Trial.
Risk Factors for the Incidence of and the Mortality due to Post-Transplant Lymphoproliferative Disorder after Hematopoietic Cell Transplantation.
Kinzel M, Dowhan M, Kalra A, Williamson TS, Dabas R, Jamani K, Chaudhry A, Shafey M, Jimenez-Zepeda V, Duggan P, Daly A, Dharmani-Khan P, Khan F, Storek J. Kinzel M, et al. Among authors: shafey m. Transplant Cell Ther. 2022 Jan;28(1):53.e1-53.e10. doi: 10.1016/j.jtct.2021.09.021. Epub 2021 Oct 1. Transplant Cell Ther. 2022. PMID: 34607072 Free article.
84 results